EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Metabolic reprogramming in aortic diseases: insights from metabolomics and therapeutic opportunities

Yingjie Liu, Linlu Zhao, Chi Zhang, Xiao Ruan, Hualong Yu, Yangpo Cao, Wenhao Ju, Haocheng Lu iD

Medical Review · 24.04.2026 · 6 (2) · 142-161

DOI: 10.1515/mr-2026-0010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Review, online erschienen am 20.03.2026. Verfasst von Yingjie Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern …. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aortic diseases (aortic aneurysm, aortic dissection, atherosclerosis) represent a substantial clinical and economic burden due to the lack of effective early diagnostic tools and mechanism-based therapies. Metabolomics, the systematic study of low-molecular-weight metabolites, has emerged as a powerful approach for elucidating pathogenesis, screening candidate biomarkers, and discovering novel drug targets. Rather than merely cataloging metabolic perturbations, this review highlights how metabolic reprogramming, particularly involving amino acid pathways, mitochondrial dysfunction, and gut microbiota-derived metabolites, actively drives aortic pathology. While specific metabolites (e.g., succinate and trimethylamine N-oxide) show promises as prognostic biomarkers, their greatest value lies in revealing actionable therapeutic nodes. Although challenges remain regarding metabolite identification, biological heterogeneity, and clinical translation, continued technological advances and integrative multi-omics approaches offer clear pathways to overcome these barriers. Ultimately, we posit that prioritizing these convergent metabolic axes, especially the gut-vascular interface, could unlock next-generation precision therapies that transcend the limitations of conventional hemodynamic management.

Schlagwörter

Stichwörter der Autor:innen

aortic aneurysmaortic dissectionatherosclerosismetabolomicstherapeutic targets

Autor:innen und Institutionen

  • Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • College of Pharmacy, Hainan Medical University, Haikou, Hainan, China.
  • National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.

ORCID-Profile: Haocheng Lu

Zitieren

APA

Liu, Y., Zhao, L., Zhang, C., Ruan, X., Yu, H., Cao, Y., Ju, W., & Lu, H. (2026). Metabolic reprogramming in aortic diseases: insights from metabolomics and therapeutic opportunities. Medical Review, 6(2), 142-161. https://doi.org/10.1515/mr-2026-0010

Vancouver

Liu Y, Zhao L, Zhang C, Ruan X, Yu H, Cao Y, et al. Metabolic reprogramming in aortic diseases: insights from metabolomics and therapeutic opportunities. Medical Review. 2026;6(2):142-161. doi:10.1515/mr-2026-0010

BibTeX
@article{Liu2026,
  author = {Liu, Yingjie and Zhao, Linlu and Zhang, Chi and Ruan, Xiao and Yu, Hualong and Cao, Yangpo and Ju, Wenhao and Lu, Haocheng},
  title = {Metabolic reprogramming in aortic diseases: insights from metabolomics and therapeutic opportunities},
  journal = {Medical Review},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {142--161},
  doi = {10.1515/mr-2026-0010}
}
Kostenlos starten →